Xconomy: Stopping Migraines Before They Hurt: NeurAxon Pursues New Pain Drug
Summary
A third trial is for a pain condition you don’t hear nearly as much about—painful bladder syndrome (aka interstitial cystitis).Interestingly, NeurAxon is bullish about this study because its compound has been designed to last 24 hours in the body before it is excreted entirely through urine.NeurAxon should have enough money until August 2010, and hopes to have positive clinical trial results in hand before then, in the first quarter of 2010, Bloch says.If NeurAxon can reach its goals, one of the very first customers will be its chief medical officer, Robert Medve, a chronic migraine sufferer himself.There are almost too many scenarios to sketch out at this point, but if NeurAxon can show that its drug has even a similar effectiveness profile to what’s already on the market, yet lasts longer and avoids the heart affects, it will be a winner, Bloch says.